Items Tagged ‘non-hodgkin lymphoma’

January 23, 2018

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma

By

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for non-Hodgkin lymphoma. About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its […]

View full entry

Tags: checkpoint inhibitor, keytruda, Mediastinal Large B-Cell Lymphoma, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, pembrolizumab, Precision Cancer Medicine


December 13, 2017

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

By

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL). Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a […]

View full entry

Tags: American Society of Hematology, ASH, Cutaneous T Cell Lymphoma, Mogamulizumab Vorinostat, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, Precision Cancer Medicine, T-Cell Non-Hodgkin's Lymphoma, targeted therapy


September 11, 2017

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced in recent years, there remains a substantial unmet need with many patients progressing or relapsing following the available therapies […]

View full entry

Tags: Azerra, Chronic Lymphocytic Leukemia, Duvelisib, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, ofatumumab, Small Lymphocytic Lymphoma